Skip to main content
SpringerLink
Log in

Herztherapeutika

  • Chapter
Arzneiverordnungs-Report 2013

Zusammenfassung

Die 2008 eingeführte Einteilung in „Herztherapeutika“ umfasst die früheren Gruppen Antiarrhythmika, Kardiaka und Koronarmittel. Die Klassifikation orientiert sich primär an therapeutischen Kriterien und weniger an pharmakologischen Wirkungen, weil Nitrate und Molsidomin ihren Hauptangriffspunkt nicht am Herzmuskel oder den Koronarien, sondern an peripheren Gefäßen haben. Die Zusammenfassung folgt dem ATC-System der WHO und erscheint wegen des kontinuierlichen Rückgangs der Verordnungen in den drei Bereichen angemessen.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 49.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Aarnoudse AL, Dieleman JP, Stricker BH (2007): Age- and gender-specific incidence of hospitalisation for digoxin intoxication. Drug Saf 30: 431–436.

    Article  PubMed  CAS  Google Scholar 

  • Ahmed A, Waagstein F, Pitt B, White M, Zannad F, Young JB, Rahimtoola S (2009): Effectiveness of Digoxin in Reducing One-Year Mortality in Chronic Heart Failure in the Digitalis Investigation Group Trial. Am J Cardiol 103: 82–87.

    Article  PubMed  CAS  Google Scholar 

  • Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R et al. (2005): Amiodaron or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 352: 225–237.

    Article  PubMed  CAS  Google Scholar 

  • Castagno D , Petrie MC, Claggett B, McMurray J (2012): Should we SHIFT our thinking about digoxin? Observations on ivabradine and heart rate reduction in heart failure. Eur Heart J 33: 1137–41.

    Article  PubMed  CAS  Google Scholar 

  • Connolly SJ, Camm AJ, Halperin JL, Joyner C, Alings M et al. PALLAS Investigators (2011): Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med 365: 2268–76.

    Google Scholar 

  • Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH et al. (1991): Mortality and morbidity in patients receiving encainide, flecainide, or placebo. N Engl J Med 324: 781–788.

    Article  PubMed  CAS  Google Scholar 

  • Fetsch T, Bauer P, Engberding R, Koch HP, Lukl J, Meinertz T, Oeff M, Seipel L, Trappe HJ, Treese N, Breithardt G (2004): Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial. Eur Heart J. 25: 1385–94.

    Article  PubMed  Google Scholar 

  • Fox K, Ford I, Steg PG, Tendera M, Ferrari R (2008) Ivabradine for patients with stable coronary artery disease and left-ventricular dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 372: 807–816.

    Article  PubMed  CAS  Google Scholar 

  • Gori T, Al-Hesayen A, Jolliffe C, Parker JD (2003): Comparison of the effects of pentaerythritol tetranitrate and nitroglycerin on endothelium-dependent vasorelaxation in male volunteers.Am J Cardiol 91: 1392–1394.

    Article  PubMed  CAS  Google Scholar 

  • Hirayama A, Kodama K, Yui Y, Nonogi H, Sumiyoshi T, Origasa H, Hosoda S, Kawai C, Japan Multicenter Investigation for Cardiovascular Diseases-Mochida Investigators (2003): Effect of trapidil on cardiovascular events in patients with coronary artery disease (results from the Japan Multicenter Investigation for Cardiovascular Diseases- Mochida [JMIC-M]). Am J Cardiol 92: 789–793.

    Google Scholar 

  • Hocini M, Jais P, Sanders P, Takahashi Y, Rotter M, Rostock T, Hsu LF, Sacher F, Reuter S, Clementy J, Haissaguerre M (2005): Techniques, evaluation, and consequences of linear block at the left atrial roof in paroxysmal atrial fibrillation: a prospective randomized study. Circulation 112: 3688–3696.

    Article  PubMed  Google Scholar 

  • Hohnloser SH, Crijns HJ, van Eickels M, Gaudin C, Page RL, Torp-Pedersen C, Connolly SJ; ATHENA Investigators (2009): Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 360: 668–678.

    Google Scholar 

  • Jurt U, Gori T, Ravandi A, Babaei S, Zeman P, Parker JD (2001): Differential effects of pentaerythritol tetranitrate and nitroglycerin on the development of tolerance and evidence of lipid peroxidation: a human in vivo study. J Am Coll Cardiol 38: 854–859.

    Article  PubMed  CAS  Google Scholar 

  • Kassenärztliche Bundesvereinigung (2012): Verordnungssteuerung. Pentalong® ist nicht verordnungsfähig. Internet: www.kbv.de/40842.html

  • Køber L, Torp-Pedersen C, McMurray JJ, Gøtzsche O, Lévy S, Crijns H, Amlie J, Carlsen J; Dronedarone Study Group (2008): Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med 358: 2678–2687.

    Google Scholar 

  • Lehmann G, Reiniger G, Beyerle A, Schomig A (1998): Clinical comparison of antiischemic efficacy of isosorbide dinitrate and molsidomine. J Cardiovasc Pharmacol 31: 25–30.

    Article  PubMed  CAS  Google Scholar 

  • Le Heuzey JY, De Ferrari GM, Radzik D, Santini M, Zhu J, Davy JM (2010): A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: The DIONYSOS Study. J Cardiovasc Electrophysiol 21: 597–605.

    Article  PubMed  Google Scholar 

  • Maresta A, Balducelli M, Latini R, Bernardi G, Moccetti T, Sosa C, Barlera S, Varani E, Ribeiro da Silva EE, Monici Preti A, Maggioni AP; STARC II Investigators (2005): Starc II, a multicenter randomized placebo-controlled double-blind clinical trial of trapidil for 1-year clinical events and angiographic restenosis reduction after coronary angioplasty and stenting. Catheter Cardiovasc Interv. 64: 375–382.

    Google Scholar 

  • McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M et al. ESC Committee for Practice Guidelines (2012): ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 33: 1787–1847.

    Google Scholar 

  • Meinertz T, Lehmacher W for the Trapidil/ISDN Study Group (2006): Trapidil is as effective as isosorbidedinitrate for treating stable angina pectoris – a multinational, multicenter, double-blind, randomized study. Clin Res Cardiol. 95: 217–223.

    Google Scholar 

  • Mest HJ (1990): Trapidil: a potent inhibitor of platelet aggregation. J Drug Dev 3: 143–149.

    Google Scholar 

  • Morrow DA, Scirica BM, Sabatine MS, de Lemos JA, Murphy SA, Jarolim P, Theroux P, Bode C, Braunwald E (2010) B-type natriuretic peptide and the effect of ranolazine in patients with non-ST-segment elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary-Thrombolysis In Myocardial Infarction 36) trial. J Am Coll Cardiol 55: 1189–1196.

    Article  PubMed  CAS  Google Scholar 

  • Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, Daubert JP, Higgins SL, Brown MW, Andrews ML for the Multicenter Automatic Defibrillator Implantation Trial II Investigators (2002): Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 346: 877–883.

    Google Scholar 

  • Nationale Versorgungsleitlinie Chronische Herzinsuffizienz. März 2012. www.versorgungsleitlinien.de/themen/herzinsuffizienz/pdf/nvl_hi_lang.pdf

  • Patten M, Maas R, Bauer P, Luderitz B, Sonntag F, Dluzniewski M, Hatala R, Opolski G, Muller HW, Meinertz T; SOPAT Investigators (2004) Suppression of paroxysmal atrial tachyarrhythmias--results of the SOPAT trial. Eur Heart J 25: 1395–404.

    Google Scholar 

  • Rathore SS, Curtis JP, Wang Y, Bristow MR, Krumholz HM (2003): Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA 289: 871–878.

    Article  PubMed  CAS  Google Scholar 

  • Roy D, Talajic M, Nattel S, Wyse DG, Dorian P, Lee KL et al. (2008) Rhythm control versus rat control for atrial fibrillation and heart failure. N Engl J Med 358: 2667–2677.

    Article  PubMed  CAS  Google Scholar 

  • Sanders GD, Hlatky MA, Owens DK (2005): Cost-effectiveness of implantable cardioverter- defibrillators. N Engl J Med 353: 1471–80.

    Article  PubMed  CAS  Google Scholar 

  • Schmiedl S, Szymanski J, Rottenkolber M, Hasford J, Thurmann PA (2007) Re: Ageand gender-specific incidence of hospitalisation for digoxin intoxication. Drug Saf 30:1171–1173; author reply 1173–1174.

    Google Scholar 

  • Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L; SHIFT Investigators (2010): Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 376: 875–885.

    Google Scholar 

  • The Digitalis Investigation Group (1997): The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 336: 525–533.

    Google Scholar 

  • Tardif JC (2007): Clinical results of I(f) current inhibition by ivabradine. Drugs 67 Suppl 2: 35–41.

    Article  PubMed  Google Scholar 

  • Tardif JC, Ford I, Tendera M, Bourassa MG, Fox K (2005): Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J 26: 2529–2536.

    Article  PubMed  CAS  Google Scholar 

  • Vaughan Williams EM (1975): Classification of antidysrhythmic drugs. Pharmac Ther B 1: 115–138.

    Google Scholar 

  • Wagner F, Gohlke-Barwolf C, Trenk D, Jähnchen E, Roskamm H (1991): Differences in the antiischaemic effects of molsidomine and isosorbide dinitrate (ISDN) during acute and short-term administration in stable angina pectoris. Eur Heart J 12: 994–999.

    PubMed  CAS  Google Scholar 

  • Wenzel P, Hink U, Oelze M, Seeling A, Isse T, Bruns K, Steinhoff L, Brandt M, Kleschyov AL, Schulz E, Lange K, Weiner H, Lehmann J, Lackner KJ, Kawamoto T, Munzel T, Daiber A (2007): Number of nitrate groups determines reactivity and potency of organic nitrates: a proof of concept study in ALDH-2-/- mice. Br J Pharmacol 150: 526–33.

    Article  PubMed  CAS  Google Scholar 

  • Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, Kellen JC, Greene HL, Mickel MC, Dalquist JE, Corley SD; Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators (2002): A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 347: 1825–1833.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institut für Experimentelle und Klinische Pharmakologie, Universitäts-Krankenhaus Eppendorf, Hamburg, Martinistraße 52, 20246

    Prof. Dr. med. Thomas Eschenhagen

Authors
  1. Prof. Dr. med. Thomas Eschenhagen
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Pharmakologisches Institut, der Universität Heidelberg, Im Neuenheimer Feld 366, 69120, Heidelberg

    Ulrich Schwabe

  2. AOK NORDWEST Die Gesundheitskasse, Edisonstraße 70, 24145, Kiel

    Dieter Paffrath

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer-Verlag Berlin, Heidelberg

About this chapter

Cite this chapter

Eschenhagen, T. (2013). Herztherapeutika. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2013. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-37124-0_27

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-37124-0_27

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-37123-3

  • Online ISBN: 978-3-642-37124-0

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation